Biosolve & NucleoSyn will be exhibiting at the next French annual Analytical Toxicology meeting organised by the SFTA in Marseille on June 5-7, 2018.
Don’t hesistate to stop by our booth to discuss your needs in term of analytical standards, reagents and high purity solvant for LC/MS application !
With over 40 years in the lipid synthesis, Biosolve & NucleoSyn produces and supplies synthetic lipids from milligrams to multi-kilos quantities. Well-characterised, these synthetic lipids are identical to their natural analogs and are well-defined, free of other lipids, non-lipids, bacterial/viral contamination.
Biosolve developed extensive experience and in-depth know-how in the R&D of new lipid based products, high quality phospholipids and other related compounds that are increasingly used as key substances (excipients, critical materials etc.) in drug formulations, drug delivery or manufacturing active pharmaceutical ingredients (APIs).
Deubiquitinases (DUBs) play important roles in pathways that are dysregulated in cancer, such as DNA repair, cell growth, and apoptosis. USP7 or HAUSP (Herpesvirus-Associated Ubiquitin-Specific Protease) is a ubiquitin specific protease or a deubiquitylating enzyme that cleaves ubiquitin from its substrates.
Since ubiquitylation (polyubiquitination) is most commonly associated with the stability and degradation of cellular proteins, HAUSP activity generally stabilizes its substrate proteins. This makes DUBs attractive potential drug targets for many cancers and neurodegenerative diseases. Ubiquitin-specific-processing proteases (USPs) are the largest class of DUBs.
Two new selective USP7 inhibitors GNE-6776 & GNE-6640 are now made available to the Research community.